M&A

AstraZeneca boosts rare disease portfolio with $1.05B Amolyt acquisition
BioSpace
Thu, 03/14/24 - 11:38 am
AstraZeneca
M&A
Amolyt Pharma
eneboparatide
hypoparathyroidism
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
Pharma Voice
Mon, 03/11/24 - 11:43 am
Moderna Therapeutics
Pfizer
vaccines
COVID-19
M&A
cancer
BiomX acquires fellow bacteria-killing virus company Adaptive Phage to accelerate phase 2 plans
Fierce Biotech
Wed, 03/6/24 - 11:26 am
BiomX
Adaptive Phage Therapeutics
M&A
cystic fibrosis
Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup
BioPharma Dive
Wed, 02/28/24 - 11:09 am
Ginkgo Bioworks
M&A
Proof Diagnostics
gene editing
Feng Zhang
Amgen details rare disease ambitions following $28B Horizon acquisition
Medical Marketing and Media
Sun, 02/25/24 - 09:04 pm
Amgen
Horizon Therapeutics
rare disease
M&A
AbbVie’s Cerevel deal hits an uncommon roadblock
BioPharma Dive
Wed, 02/21/24 - 11:10 am
AbbVie
Cerevel Therapeutics
M&A
FTC
antitrust
Novo Nordisk and Catalent deal: net positive or negative for industry?
Biopharma Reporter
Tue, 02/20/24 - 11:06 am
Novo Nordisk
Catalent
M&A
Wegovy
Ozempic
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
Reuters
Thu, 02/15/24 - 11:19 am
GSK
Aiolos Bio
M&A
Cancer and Neuroscience Led 2023 VC, M&A Investment in Biopharma
BioSpace
Wed, 02/14/24 - 11:36 am
funding
M&A
venture capital
cancer
Neuroscience
AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule
Fierce Pharma
Mon, 02/12/24 - 11:07 pm
AbbVie
Immunogen
M&A
Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
Amgen makes progress with its Horizon prize Tepezza, but there's much work left to do
Fierce Pharma
Wed, 02/7/24 - 09:22 pm
Amgen
Horizon Therapeutics
M&A
Tepezza
Gilead will not buy Tizona after paying $300M for the right to do so
Fierce Biotech
Wed, 02/7/24 - 11:17 am
Gilead Sciences
Tizona Therapeutics
M&A
oncology
Amgen earnings boosted by Horizon deal, Gilead quarterly revenue drops
Medical Marketing and Media
Tue, 02/6/24 - 11:41 pm
Amgen
Gilead Sciences
earnings
Horizon Therapeutics
M&A
Novo Holdings acquires Catalent in $16.5B deal, aiming to boost Wegovy production as demand soars
Medical Marketing and Media
Mon, 02/5/24 - 11:06 pm
Novo Nordisk
Catalent
drug manufacturing
Wegovy
M&A
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
NASDAQ.com/Reuters
Mon, 02/5/24 - 11:28 am
Novartis
M&A
MorphoSys
cancer
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
CNBC
Mon, 02/5/24 - 10:10 am
Novo Nordisk
Catalent
drug manufacturing
M&A
Wegovy
Ozempic
BMS more likely to bet on bolt-ons after recent buying spree
Fierce Biotech
Fri, 02/2/24 - 11:59 am
Bristol Myers Squibb
M&A
earnings
Rite Aid Completes $575 Million PBM Sale To MedImpact
Forbes
Fri, 02/2/24 - 11:41 am
Rite Aid
PBMs
M&A
Elixir
MedImpact
Will Abbott Have a Strong Year for M&A?
Medical Devices and Diagnostics Industry
Thu, 02/1/24 - 11:04 pm
Medtech
Abbott Labs
M&A
earnings

Pages